Basic Dasatinib Information

• International Nonproprietary Name (INN): Dasatinib
• Brand names available in Australia: Sprycel
• ATC Code: L01EA02
• Forms & dosages: Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg)
• Manufacturers in Australia: BMS Australia Pty Ltd
• Registration status in Australia: Schedule 4 (S4 — Prescription only)
• OTC / Rx classification: Prescription only (Rx)

Latest Research Highlights

Recent studies indicate that dasatinib has shown robust effectiveness in the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Data from Australia aligns closely with global findings from ongoing research (2022–2025), illustrating significant advances in patient outcomes. Key improvements include: - Enhanced survival rates - Reduced disease progression - Better overall safety profiles Notably, patients treated with dasatinib in clinical trials have experienced fewer adverse effects compared to earlier treatment regimens, highlighting its tolerability.

Clinical Trial	Participant Demographics	Key Findings	Safety Observations
Trial A	Adults, Australia	Improved overall survival	Low incidence of severe side effects
Trial B	Pediatric, International	High response rates	Monitored for potential cardiovascular issues

Clinical Effectiveness in Australia

In Australia, dasatinib’s health outcomes reflect positively within the pharmaceutical benefits scheme (PBS) data and Therapeutic Goods Administration (TGA) monitoring frameworks. Evidence demonstrates that patients are achieving significant responses to treatment, with remission rates standing out when compared to other therapies. Statistics reveal that approximately: - **70% of patients** achieve a complete cytogenetic response within the first year of treatment. - The long-term remission rates improve notably over two years. When comparing dasatinib to other options available on the PBS, its effectiveness in CML and ALL is a defining factor in its preference among clinicians.

Indications & Expanded Uses

Dasatinib is primarily approved in Australia, under TGA guidelines, for adults and children diagnosed with Ph+ CML and ALL. It represents an innovative approach to treating these conditions, particularly in cases resistant to older therapies. In clinical settings, off-label practices have been observed, with dasatinib being used to treat other malignancies. This off-label use underscores its evolving role within oncology treatment paradigms in Australian healthcare.

Composition & Brand Landscape

Dasatinib’s active ingredient is the BCR-ABL/SRC family tyrosine kinase inhibitor, indicating its role in targeted therapy. The chemical structure aids in inhibiting the proliferation of cancer cells associated with certain leukaemia types. The most prominent brand of dasatinib in Australia is Sprycel. Various dosages are available, ensuring tailored treatment based on patient needs. Generics have also entered the market, offering additional options through the PBS. Manufacturers include: - Bristol-Myers Squibb - Teva - Accord Healthcare Local packaging typically comes in blister packs, making medication adherence easier for patients undergoing treatment.

Contraindications & Special Precautions

Identifying high-risk groups is vital in the context of dasatinib treatment in Australia. Specific populations, such as Indigenous Australians, the elderly, and pregnant individuals, require careful consideration when prescribing this medication. Patients may need to navigate daily-life restrictions, particularly concerning: - Driving capabilities - Workplace safety Monitoring for potential adverse reactions is also crucial, given dasatinib’s side effect profile. Regular assessments can help manage risks effectively, contributing to better health outcomes.

Dosage Guidelines

Understanding the proper dosage of dasatinib, especially in Australia, is vital for effective treatment.

For adults, the standard recommended dosages are:

• Chronic phase Ph+ CML: 100 mg orally once daily
• Accelerated or blast phase CML and Ph+ ALL: 140 mg orally once daily

Children typically receive a dosage based on body surface area:

• 60 mg/m² once daily, with a maximum of 100 mg/day.

Factors for dosage adjustments include:

• Weight: Children require tailored dosing based on their size.
• Comorbidities: Elderly patients need careful monitoring.
• Hepatic or renal impairment: Dose adjustments may be necessary.

It is essential to monitor patients closely, especially for those with existing health concerns. In case of missed doses, instructions recommend taking the dose as soon as remembered, unless close to the next scheduled dose. There’s no specific antidote in case of overdose, making adherence to prescribed intervals crucial.

Interactions Overview

When taking dasatinib, food and drink interactions can be influential, particularly for those with Australian dietary habits. Avoiding grapefruit juice is essential, as it may increase the effects of dasatinib due to its interaction with drug metabolism.

Common drug interactions monitored by the TGA and Australian e-health systems include:

• Antacids and proton pump inhibitors, which can reduce dasatinib effectiveness.
• Other medications that impact CYP3A4 enzymes, altering dasatinib levels in the body.

Pharmaceutical care should emphasise these interactions. Patients should be educated about their full medication regimen, especially if they are taking multiple prescriptions or over-the-counter medications that could interfere with treatment.

Cultural Perceptions & Patient Habits

Discussions within Australian patient forums reveal varied cultural attitudes toward dasatinib and its role in cancer treatment. There’s a substantial focus on natural remedies and alternative therapies, which sometimes lead to hesitance in adopting conventional treatments like dasatinib.

Access disparities are apparent between urban and rural settings. In urban areas, pharmacies and telehealth services provide immediate access to treatments. In contrast, rural patients often face challenges such as:

• Limited pharmacy availability;
• Greater reliance on mail-order prescriptions;
• Price sensitivity and PBS subsidies influencing choices.

These factors significantly shape patient habits, making discussions around dasatinib more nuanced. Patients in rural areas may seek local support groups to navigate these challenges, highlighting the community's role in healthcare access and decision-making.

Availability & Pricing Patterns

Dasatinib is widely available across major pharmacy chains in Australia, like Chemist Warehouse and Priceline, ensuring that those with prescriptions can easily access the drug.

Online pharmacy options have also surged, particularly with the rise of telehealth in Australia. This trend allows patients to receive prescriptions without needing to visit a clinic physically. However, pricing disparities exist:

• PBS pricing is considerably more affordable than private pricing.
• Local prescriptions generally afford lower costs, ensuring that patients can manage their treatment within budget.

Patients are encouraged to explore these avenues to find the most cost-effective solutions for their dasatinib needs, ensuring adherence to treatment plans while maintaining financial stability.

Comparable Medicines and Preferences

Patients often wonder about alternatives to dasatinib when exploring their treatment options for Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Several competitors are available in Australia, and understanding their pros and cons can aid in making informed decisions. Here’s a quick overview:

• Imatinib (Gleevec): First-line treatment for CML. Generally well-tolerated but may not be effective for some resistant cases.
• Nilotinib (Tasigna): More potent than imatinib, with a lower chance of disease progression, but may cause more severe side effects like cardiovascular events.
• Bosutinib (Bosulif): Effective in patients resistant to imatinib or dasatinib. Some gastrointestinal side effects are common.
• Ponatinib: Used for resistant cases, especially in patients with the T315I mutation but comes with a higher risk for severe side effects.

This list outlines some of the choices available, and a checklist can help simplify the decision process:

• Effectiveness
• Side Effects
• Cost
• Dosing Convenience

Consult with a healthcare professional to weigh these options and find the right fit.

FAQ Section

Many patients have questions when starting dasatinib. Here are some common inquiries:

What are the side effects? Side effects can include myelosuppression, peripheral oedema, and gastrointestinal issues, alongside the risk of cardiovascular effects.

How is dasatinib administered? It’s an oral medication taken once daily, typically in tablet form.

Are there generic versions available? Yes, dasatinib is available in various generic formulations, making it more accessible for patients.

What should I do if I miss a dose? Take the missed dose as soon as remembered unless it’s close to the next scheduled dose; never double up.

Guidelines for Proper Use

Education from Australian pharmacists is vital in ensuring proper use of dasatinib. They often engage in relatable conversations to clarify medication adherence and the importance of consistent dosing. Relevant guidelines highlight:

• Always take dasatinib at the same time each day. This helps maintain an even level of the medication in the body.
• Monitor for side effects. Understanding what to expect can lessen anxiety and improve management strategies.
• Seek help for unusual symptoms. Contact healthcare providers immediately for concerns regarding cardiac issues or severe reactions.
• Adhere to medication storage recommendations. Keep dasatinib in a cool, dry place away from light to maintain its effectiveness.

This practical approach promotes adherence and enhances the overall treatment experience. Don’t hesitate to reach out to healthcare professionals with any questions or concerns.

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Perth	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Hobart	Tasmania	5–9 days
Canberra	Australian Capital Territory	5–7 days
Gold Coast	Queensland	5–9 days
Geelong	Victoria	5–9 days
Coffs Harbour	New South Wales	5–9 days
Sunshine Coast	Queensland	5–9 days
Newcastle	New South Wales	5–9 days
Townsville	Queensland	5–9 days
Wollongong	New South Wales	5–9 days
Ballarat	Victoria	5–9 days